Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Revolution Medicines revenue 2017–2026What is revenue? Revenue is the money a company brings in from selling its goods and services over a period, before any costs. It is the top line of the income statement.
Revolution Medicines's revenue in Q3 FY2026, the three months to 30 September 2026, was 197.56M USD, with no change to compare on the same quarter a year before. Revolution Medicines's revenue in fiscal year 2025 was 0.00 USD, with no change to compare on the year before.
Last updated 8 Nov 2026 · Next report 24 Feb 2027
Revenue
Growth
| Fiscal year | Period ending | Revenue | Growth | Gross profit | Net income |
|---|---|---|---|---|---|
| TTM | 30 Sept 2026 | — | — | — | -1.87B |
| FY2025 | 31 Dec 2025 | 0.00 | — | -16.56M | -1.13B |
| FY2024 | 31 Dec 2024 | 0.00 | -100.00% | 0.00 | -600.09M |
| FY2023 | 31 Dec 2023 | 11.58M | -67.27% | 11.58M | -436.37M |
| FY2022 | 31 Dec 2022 | 35.38M | +20.38% | 35.38M | -248.71M |
| FY2021 | 31 Dec 2021 | 29.39M | -31.62% | 29.39M | -187.09M |
| FY2020 | 31 Dec 2020 | 42.98M | -14.10% | 42.98M | -108.16M |
| FY2019 | 31 Dec 2019 | 50.04M | +148.16% | 50.04M | -47.66M |
| FY2018 | 31 Dec 2018 | 20.17M | — | 20.17M | -41.79M |
| FY2017 | 31 Dec 2017 | 0.00 | — | -26.59M | -31.13M |
| Quarter | Period ending | Revenue | Growth on a year before | Gross profit | Net income |
|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 197.56M | — | 197.23M | -407.46M |
| Q2 FY2026 | 30 Jun 2026 | 0.00 | — | 0.00 | -644.37M |
| Q1 FY2026 | 31 Mar 2026 | 0.00 | — | -4.54M | -453.82M |
| Q4 FY2025 | 31 Dec 2025 | 0.00 | — | -4.70M | -364.89M |
| Q3 FY2025 | 30 Sept 2025 | 0.00 | — | 0.00 | -305.21M |
| Q2 FY2025 | 30 Jun 2025 | 0.00 | — | 0.00 | -247.79M |
| Q1 FY2025 | 31 Mar 2025 | 0.00 | — | 0.00 | -213.42M |
| Q4 FY2024 | 31 Dec 2024 | 0.00 | -100.00% | 0.00 | -194.57M |
| Q3 FY2024 | 30 Sept 2024 | 0.00 | — | 0.00 | -156.29M |
| Q2 FY2024 | 30 Jun 2024 | 0.00 | -100.00% | 0.00 | -133.23M |
| Q1 FY2024 | 31 Mar 2024 | 0.00 | -100.00% | 0.00 | -116.00M |
| Q4 FY2023 | 31 Dec 2023 | 742.00K | -95.16% | — | -161.54M |
| Q3 FY2023 | 30 Sept 2023 | 0.00 | -100.00% | 0.00 | -108.43M |
| Q2 FY2023 | 30 Jun 2023 | 3.82M | -58.05% | — | -98.30M |
| Q1 FY2023 | 31 Mar 2023 | 7.01M | -7.44% | — | -68.10M |
| Q4 FY2022 | 31 Dec 2022 | 15.33M | +62.05% | — | -56.51M |
| Q3 FY2022 | 30 Sept 2022 | 3.36M | +204.81% | — | -73.33M |
| Q2 FY2022 | 30 Jun 2022 | 9.12M | +4.81% | — | -61.22M |
| Q1 FY2022 | 31 Mar 2022 | 7.58M | -25.20% | — | -57.65M |
| Q4 FY2021 | 31 Dec 2021 | 9.46M | +8.10% | — | -52.68M |
| Q3 FY2021 | 30 Sept 2021 | 1.10M | -91.30% | — | -52.94M |
| Q2 FY2021 | 30 Jun 2021 | 8.70M | -13.24% | — | -44.30M |
| Q1 FY2021 | 31 Mar 2021 | 10.13M | -12.26% | — | -37.18M |
| Q4 FY2020 | 31 Dec 2020 | 8.75M | -27.61% | — | -34.20M |
| Q3 FY2020 | 30 Sept 2020 | 12.66M | +1.24% | — | -27.22M |
| Q2 FY2020 | 30 Jun 2020 | 10.03M | -18.37% | — | -27.22M |
| Q1 FY2020 | 31 Mar 2020 | 11.55M | -12.30% | — | -19.52M |
| Q4 FY2019 | 31 Dec 2019 | 12.09M | +16.83% | — | -14.60M |
| Q3 FY2019 | 30 Sept 2019 | 12.51M | — | — | -12.82M |
| Q2 FY2019 | 30 Jun 2019 | 12.28M | — | — | -10.12M |
| Q1 FY2019 | 31 Mar 2019 | 13.17M | — | — | -10.13M |
| Q4 FY2018 | 31 Dec 2018 | 10.35M | — | — | -11.34M |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
Revolution Medicines revenue growth by segment
FY2022 against FY2021
Collaboration Revenue35.38M
+20.4%
Revolution Medicines revenue by segment over time
Collaboration Revenue Collaboration Revenue Related Party
See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Income statement
Common questions about Revolution Medicines's revenue
Source: Financial Modeling PrepVerified against SEC filings